STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(e)
On March 23, 2017, Stellar Biotechnologies, Inc. (the Company)
held its 2017 annual general meeting of shareholders (the Annual
Meeting). At the Annual Meeting, the Companys shareholders
approved the Companys 2017 Incentive Compensation Plan. A
description of the material terms and conditions of the 2017
Incentive Compensation Plan appears on pages 35-45 of the
Companys definitive proxy statement for the Annual Meeting filed
with the Securities and Exchange Commission on February 1, 2017
and such description is incorporated herein by reference. This
summary is qualified in its entirety by the full text of the 2017
Incentive Compensation Plan, which is filed herewith as Exhibit
10.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
| Item 5.07. |
Submission of Matters to a Vote of Security Holders. |
Set forth below are the matters submitted to the shareholders at
the Annual Meeting, all of which were approved:
|
the election of seven (7) directors to serve on the Companys Board of Directors until the Companys annual general meeting of shareholders to be held in 2018 or until their successors are duly elected and qualified; |
|
the ratification of the appointment of Moss Adams LLP as the Companys auditors and independent registered public accounting firm for the fiscal year ending September 30, 2017; and |
|
the approval of the Companys 2017 Incentive Compensation Plan. |
The final voting results with respect to each matter are set
forth below.
Election of Directors
| NOMINEE | FOR VOTES | WITHHELD VOTES | ABSTAIN | BROKER NON-VOTES |
| Tessie M. Che | 1,402,807 | 216,655 | 3,300,035 | |
| Paul Chun | 1,401,459 | 218,003 | 3,300,035 | |
| David L. Hill | 1,564,896 | 54,566 | 3,300,035 | |
| Daniel E. Morse | 1,537,645 | 81,817 | 3,300,035 | |
| Frank R. Oakes | 1,565,743 | 53,719 | 3,300,035 | |
| Charles V. Olson | 1,406,768 | 212,694 | 3,300,035 | |
| Mayank D. Sampat | 1,401,681 | 217,781 | 3,300,035 |
Ratification of the Appointment of Moss Adams LLP as
the Companys Auditors and Independent Registered Public
Accounting Firm for the Fiscal Year Ending September 30,
2017
| FOR VOTES | WITHHELD VOTES | ABSTAIN | BROKER NON-VOTES |
| 4,840,165 | 79,332 |
Approval of 2017 Incentive Compensation
Plan
| FOR VOTES | AGAINST VOTES | ABSTAIN | BROKER NON-VOTES |
| 1,311,522 | 307,940 | 3,300,035 |
| Item 8.01. | Other Events. |
Effective March 23, 2017, the Board approved the following
Chairpersons and members of each of its standing committees:
| Nominating and Corporate | ||
| Audit Committee | Compensation Committee | Governance Committee |
| Mayank D. Sampat, Chair | David L. Hill, Chair | Paul Chun, Chair |
| David L. Hill | Mayank D. Sampat | David L. Hill |
| Paul Chun | Daniel E. Morse | Mayank D. Sampat |
| Paul Chun | ||
| Charles V. Olson |
| Item 9.01. | Financial Statements and Exhibits. |
(d)Exhibits.
| Exhibit No. | Description | |
| 10.1 | 2017 Incentive Compensation Plan. |
About STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT)
Stellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases. The Company’s core business is developing and commercializing Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications. The Company’s Stellar KLH product offerings include Stellar KLH protein for conjugation and as carrier molecule in immunotherapy development; Stellar KLH protein and enzyme-linked immunosorbent assay (ELISA) test kits for immune function testing, and Custom KLH formulations, adjuvants, conjugations and fill finishes for preclinical research and drug development applications. STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT) Recent Trading Information
STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT) closed its last trading session down -0.02 at 1.60 with 36,014 shares trading hands.